AVR
Anteris Technologies Ltd
🇦🇺 ASX
🩺 HEALTH CARE
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 0.90%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
5
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Anteris Technologies Ltd. is a structural heart company, which engages in research, develops, commercializes, and distributes medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in designing, developing, and commercializing medical devices. The Company’s lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. The company is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.
📈 Performance
Price History
-22.50%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$9.30
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in AVR
5
📊 Total Capital Earnings
$-334.31
🔃 Average investment frequency
62 weeks
💵 Average investment amount
$1,176
⏰ Last time a customer invested in AVR
158 days
AVR investor breakdown
💵 Income of investors
More than 200k
150k - 200k
20%
100k - 150k
20%
50k - 100k
60%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
60%
35 - 90
40%
🙋 Legal gender of investors
Female
80%
Male
20%
Pearlers who invest in AVR also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
4.35%
📊 Share price
$104.33 AUD
⛳️ DIVERSIFIED
🧱 MATERIALS
💸 FINANCIALS
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
13.23%
📊 Share price
$134.96 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
19.63%
📊 Share price
$61.01 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
🙌 Performance (5Yr p.a)
-5.00%
📊 Share price
$0.04 AUD
🧬 BIOTECHNOLOGY
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.
🙌 Performance (5Yr p.a)
82.15%
📊 Share price
$12.36 AUD
📦 LOGISTICS
Want more shares? Try these...
Avira Resources Ltd. operates as an exploration company, which engages in the exploration of tin, gold and copper properties. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2013-01-09. The Company’s e Puolalaki Project comprises a single exploration permit (Puolalaki nr 100) centered over a syn-orogenic gabbro intrusion that hosts the nickel mineralization. In addition to the Ni-Cu-Co mineralization at Puolalaki, the project also includes high-grade gold mineralization across two zones within the metasediments and metavolcanics surrounding the gabbro. The project is located in Sweden’s premier Gallivare mining district. In addition to the Puolalaki Project in Sweden, the Company holds two tenement packages within the Paterson Range province in the Northwest of Western Australia which is host to a number of substantial gold, copper and manganese mines and deposits, including the Telfer gold-copper mine. Its projects are situated in the Yeneena basin sedimentary rock formation that hosts both the Nifty and Maroochydore copper deposits and the Woody Woody Manganese mine.
🙌 Performance (5Yr p.a)
-10.00%
📊 Share price
$0.00 AUD
⛏️ MINING
Advance Metals Ltd. engages in the business of investing in renewable energy and coal exploration. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-12-20. The Company’s projects include Augustus Polymetallic, Garnet Skarn Deposit, and Anderson Creek Gold. The 100% owned Augustus polymetallic project covers approximately 1,741 contiguous acres. The project resides in the central western part of Arizona, approximately 140 kilometers (km) (87 mi) northwest of Phoenix, AZ. The Garnet Creek Project Area is located in Adams County, Idaho (ID), United States, at the southern end of the Seven Devils Mountains. The project comprises 2527 acres of unpatented mineral lands held by Advance Metals. The Anderson Creek Gold project is located in the prolific mining region of Lemhi County, Idaho. The project is located in the Gibbonsville Mining District in northern Lemhi County. The project consists of over 117 claims.
🙌 Performance (5Yr p.a)
3.50%
📊 Share price
$0.03 AUD
⛏️ MINING